Business Context and Reporting Period
This Form 8-K Current Report was filed by Achieve Life Sciences, Inc. on March 29, 2023. The report details significant changes to the composition of the Company's Board of Directors, effective March 29, 2023, pursuant to a Cooperation Agreement dated March 1, 2023.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
- Appointment of New Directors: The Board appointed Stuart Duty, Thomas King, and Thomas Sellig as new directors effective March 29, 2023.
- Departure of Directors: Donald Joseph, Martin Mattingly, and Jay Moyes announced they will not stand for reelection at the 2023 Annual Meeting. They will serve until their terms expire at that meeting.
- Reason for Departure: The outgoing directors' decisions were not the result of any disagreement with the Company regarding operations, policies, or practices.
Compensation and Governance Details
The incoming directors will be compensated under the Company's Non-Employee Director Compensation Program:
- Cash Retainer: Each incoming director receives a pro rata portion of the $40,000 annual retainer for the remainder of the fiscal year ending December 31, 2023.
- Initial Equity Award: Each incoming director received a stock option to purchase 24,000 shares of Common Stock at the closing sale price on the grant date. These options vest monthly over three years.
- Future Annual Awards: Incoming directors are eligible for customary annual equity compensation, currently consisting of a stock option to purchase 23,250 shares, vesting monthly over three years.
- Indemnification: Standard indemnification agreements were entered into with each incoming director.
Investor Verification Checklist
- Verify the terms of the Cooperation Agreement filed as Exhibit 10.1 to the March 6, 2023 Form 8-K to understand the strategic relationship with Dialectic Capital Management, LP.
- Review the Non-Employee Director Compensation Program details to assess the total potential equity dilution from the new and future annual awards.
- Confirm the 2023 Annual Meeting date to determine when the outgoing directors' terms officially conclude.
- Check the press release (Exhibit 99.1) for any additional context regarding the strategic rationale for the board changes.